Most side effects for both will happen at the start of treatment and when you increase your dose
Rus M et al
intravenously (IV) once a week
licensed UK options include orlistat, semaglutide 2.4 mg (Wegovy), and tirzepatide (Mounjaro), and your GP can also advise on clinical trial eligibility
Important nteractions one should check out for: Corticosteroids additive hyperglycemic Thiazide diuretics additive glucose elevation Non-selective beta-blockers (e.g., propranolol) can mask hypoglycemia symptoms in insulin/sulfonylurea users CYP1A2 modulators (e.g., smoking cessation during admission) can raise olanzapine levels unexpectedly QT-prolonging co-prescriptions (fluoroquinolones, macrolides, ondansetron) additive QTc risk Anticholinergic burden can worsen diabetic gastroparesis 3.Interventions Baseline and periodic fasting glucose, lipid panel, weight/BMI Track HbA1c trend from olanzapine initiation Discuss risk-benefit of lower metabolic-risk alternatives (e.g., aripiprazole) where clinically appropriate Don't dismiss deteriorating glucose control as "just illness stress" screen actively This is the kind of case that reminds us why the pharmacist's seat at the ward round table matters catching interactions that aren't always obvious on a first glimpse of a prescription
The introduction of OLYMVIQ marks a step forward in making advanced, once-weekly GLP-1 therapy more accessible to those who need it most
